Carasent Ab · OMXSTO:CARA
Carasent Ab — Q4 2024 Earnings Presentation
14 slides from Carasent Ab's earnings presentation, Feb 13, 2025
Slide 1: Interim report Q4
Interim report Q4 13 February 2025 Driving efficiency and quality in the world of care
Slide 2: Agenda
Agenda Todays presenters 1 Company update 2 Financial update Daniel Öhman Svein Martin Bjørnstad CEO CFO
Slide 3: Highlights Q4
Highlights Q4 3 Update ▪ Performance in line with targets ▪ Acquisition of Data-AL and relisting to Nasdaq Stockholm completed ▪ Good progress in large development projects; Surgery, NLL, Volvat, Patient platforms and Webdoc X ▪ Bankruptcies for Webdoc customers put higher pressure on new sales Grow
Slide 4: Scaling into the cost base
Scaling into the cost base 4 Significant improvement through cost efficiencies and growth Revenue growth is the key to drive margins going forward +14 million +24% 4 0 2 9 6 70 59 +13 million 7 4 Q4-23 Q4-24 -3 Recurring revenues Confrere -9 Consulting & other Signed not implemented QRR Q4-23 Q4-24
Slide 5: In line with targets on all metrics
In line with targets on all metrics 5 2023A 2024 targets 2024 Outcome NOK NOK NOK Excluding Data-AL Excluding Data-AL Revenue 244m 270m NOK 271m in line Adj EBITDA 21m >40m 41m in line Adj EBITDA – capex -45m Neutral -0.5m in line Adj EBITDA – capex excl. Webdoc X -18m 20m 19m in line 1: NOK figures
Slide 6: Journey Ahead
Journey Ahead 6 Strong organic • Key to deliver implementation projects and new development on time Big interest in surgery, first pilot is now up and running growth • Efficient use of • Continuous efficiency gains including replacing roles and use of AI Cost control through prioritization and dilig
Slide 7: Financial update Q4 2024
Carasent Capital Market Day 2023 Financial update Q4 2024
Slide 8: Carasent – Q4 financial highlights
Carasent – Q4 financial highlights 8 304 15% 15% Million contracted ARR Organic recurring Adj. EBITDA margin per Q4 2024 revenue growth 17% 111% 5% Contracted ARR growth Net retention rate Adj. EBITDA – capex (organic) margin
Slide 9: Strong YoY improvements
Strong YoY improvements 9 NOKm Q4 2024 Q4 2023 YoY growth FY 2024 FY 2023 ▪ Strong underlying organic growth for all Webdoc 35 30 18% 135 113 product categories Other EHR 21 15 43% 65 56 Platform products 14 14 0% 53 54 ▪ Consulting revenues up significantly – Consulting and other 9 6 50% 23 22 prio
Slide 10: Operating Leverage
Operating Leverage 10 Heavy investment period behind us, significant margin expansion ahead Adj. EBITDA less Capex (excl. Germany) 12 Q1-23 – Q4-24, NOKm 12 Adj. EBITDA-Capex margin 10 improvement from -18% in Q1-23 8 to +9% in Q4-24 on the back of: 11% • Continued solid revenue 9% growth 7% 8 7 6 5
Slide 11: 17% organic growth in contracted ARR
17% organic growth in contracted ARR 11 ARR growth driven by strong upsell, continued low churn and new contracts Implemented ARR Signed, not implemented ARR +17% +31% 304 18 270 34 18 232 5 9 24 8 +4% +13% -2% 287 Q4’23 ARR Net upsale Churn New customers Q4’24 ARR M&A Q4’24 ARR (excl. Confrere) (co
Slide 12: ~18m FCF improvement YoY
~18m FCF improvement YoY 12 NOKm Q4 2024 Q4 2023 YTD 2024 YTD 2023 ▪ Significant improvements in profitability and operating cash Revenue 78.7 64.4 275.3 245.2 flow YTD Reported EBITDA -8.7 6.1 11.6 13.4 ▪ High one-off costs – some Change in working capital 25.0 -1.5 26.1 -17.4 invoices will be paid
Slide 13: Converting 2025 targets to SEK
Converting 2025 targets to SEK 13 Fx rate at 2025 target publication of 2025 targets ▪ Changed reporting targets currency from NOK NOK SEK to SEK following relisting Revenue NOK 360m 0.97 SEK ~350m ▪ Targets converted to SEK based on fx rate EBITDA 85-90m 0.97 82-87m at time of publication EBITDA –
Slide 14: Q&A
Q&A